Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma

Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma.

To determine safety profile of immunotherapy with natural killer cells and activated expanded (NKAEs) after salvage chemotherapy in relapsed/refractory paediatric T cell lymphoblastic leukaemia and lymphoma.

Inclusion Criteria:

• Patients aged between 0 and 21 years with relapsed or refractary acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma.
• Lansky Index > 60%.
• Left ventricular ejection fraction > 39%.
• Negative HIV serology.
• Provide informed consent in accordance with current legislation.

Exclusion Criteria:

• Patients with a history of poor compliance.
• Patients not valid after psycho-social evaluation
• Severe (4) functional organ disorders (hepatic, renal, respiratory) according to NCI CTCAE v3 criteria